Author:
Yang Zhen,Shao Yuan,Huang Hua,Liu Yang,Wang Zeyuan,Wang Yong
Funder
Innovative Research Group Project of the National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708
2. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R et al (2022) Cancer incidence and mortality in China, 2016. J Natl Cancer Center 2:1–9. https://doi.org/10.1016/j.jncc.2022.02.002
3. Ma CG, Ye DW, Li CL, Zhou FJ, Yao XD, Zhang SL et al (2008) Epidemiology of prostate cancer from three centers and analysis of the first-fine hormonal therapy for the advanced disease. Zhonghua wai ke za zhi [Chin J Surg] 46:921–925
4. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244. https://doi.org/10.1001/jama.294.2.238
5. Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G et al (2020) Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol 77:365–372. https://doi.org/10.1016/j.eururo.2019.09.004